Summary of Presentations from a Novartis-Supported Satellite Symposium, held at the 24th ERS Congress, Munich, Germany, on 7th September 2014
Chairperson: Roland Buhl1
Speakers: Gary Anderson,2 William Busse,3 Jan Lötvall,4 David Price5
1. Mainz University Hospital, Mainz, Germany
2. University of Melbourne, Melbourne, Australia
3. University of Wisconsin, Madison, Wisconsin, USA
4. University of Gothenburg, Gothenburg, Sweden
5. Research in Real Life, Singapore
Disclosure: Prof Buhl has provided lecturing and consulting activities for Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Novartis, Roche, Takeda, and Teva. He receives research support (Mainz University) from Boehringer Ingelheim, GSK, Novartis, and Roche. Prof Anderson has received compensation from Boehringer Ingelheim, AstraZeneca, MundiPharma, Novartis, Menarini, Takeda, and GSK for participating in meetings and advisory boards. Prof Busse is a consultant for Novartis, GSK, Genentech, and Roche. He serves on data monitoring boards and study oversight committees for Boston Scientific, Genentech, and ICON, and has research/organisational interests in AAAAI, ATS, AAP, ACAAI, AAI, ACP, CIM, NHLBI, and NIAID. Prof Lötvall has relationships with AbdiIbrahim, Aerovant, AstraZeneca, GSK, Novartis, MSD, and UCB. Prof Price is a board member for Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva. He provides consultancy for Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Meda, Mundipharma, Napp, Novartis, Pfizer, and Teva. He has grants and grants pending from the UK National Health Service, British Lung Foundation, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GSK, Meda, Merck, Mundipharma, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, and Zentiva. He has received payments for lectures/speaking/manuscripts/educational materials from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda, and Teva. He owns shares in AKL Ltd., which produces phytopharmaceuticals and owns 80% of Research in Real Life Ltd. and its subsidiary social enterprise, Optimum Patient Care. He has unrestricted funding for investigator-initiated studies from Aerocrine, AKL Ltd., Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva.
Acknowledgements: Writing assistance was provided by Dr Nicola Ray apothecom scopemedical.
Support: Medical writing assistance was funded by Novartis. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Novartis.
Citation: EMJ Respir. 2014;2:28-32.
The meeting discussed the current understanding of the role of immunoglobulin E (IgE) in asthma, and anti-IgE strategies in the treatment of severe asthma. Prof Gary Anderson provided an overview of the integral role of IgE in the inflammatory pathways involved in the pathogenesis of severe asthma and the development of omalizumab (Xolair®), an anti-IgE therapy. Prof William Busse presented some of the clinical findings on the use of omalizumab for virus-provoked asthma. Prof Jan Lötvall discussed how phenotyping could improve the development of patient-targeted treatment strategies in asthma. Finally, Prof David Price discussed how changes to the clinical management of patients with severe asthma could improve patient outcomes.